According to a Reuters report, a closely-watched Gilead Sciences Inc (GILD.O) experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China, but the drugmaker said the findings were inconclusive because the study was terminated early.
Gilead shares closed down 4.3% after the data was inadvertently released and first reported by the Financial Times.
What is it? It comes days after another report detailed rapid recovery in fever and respiratory...
http://mfame.guru/gilead-allege-inappropriate-characterizations-of-its-covid19-drug-trial-data/